Crystalys Therapeutics, a clinical-stage biopharmaceutical company focusing on developing next-generation therapies for gout, announced the closing of an oversubscribed $130 million Series B financing to support late-stage global clinical development and commercialization preparation of dotinurad, a once-daily oral URAT1 inhibitor for the treatment of gout. Crystalys is one of AN Venture Partners’ (ANV) portfolio companies.

The round was led by Frazier Life Sciences, with participation from Wellington Management, HBM Healthcare Investments, and other new investors, as well as all existing investors, including ANV. 

Proceeds will advance the company's two ongoing registration-directed trials and studies, collectively evaluating the safety and efficacy of dotinurad in patients with gout. Dotinurad is already approved in multiple Asian markets, where it has demonstrated a compelling safety and efficacy profile.

For the full announcement, please see Crystalys Therapeutics' press release here.

About Crystalys Therapeutics

Crystalys Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California, focused on transforming the treatment of gout. The company’s lead candidate, dotinurad, is a next-generation, once daily oral, URAT1 inhibitor in clinical development as a second-line therapy aimed to reduce uric acid, gout flares and tophi. Dotinurad was invented by Fuji Yakuhin and has obtained regulatory approval in Japan, China, the Philippines and Thailand. With best-in-class potential for both safety and efficacy, dotinurad is supported by clinical data from multiple Asian markets where it is approved.For more information, please visit Crystalys Therapeutics’ website.

Media Contacts 

Email: info@an.vc